SECUKINUMAB IMPROVES MINIMAL DISEASE ACTIVITY RESPONSE RATES IN PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS: DATA FROM THE RANDOMIZED PHASE 3 STUDY, FUTURE 2

被引：4
|
作者：
Coates, L. C. [1 ,2 ]
Mease, P. [3 ]
Kirkham, B. [4 ]
McLeod, L. D. [5 ]
Mpofu, S. [6 ]
Karyekar, C. [7 ]
Gandhi, K. [7 ]
机构：
[1] Univ Leeds, Leeds Inst Rheumat & Musculoskeletal Med, Leeds, W Yorkshire, England
[2] Leeds Teaching Hosp NHS Trust, Leeds Musculoskeletal Biomed Res Unit, Leeds, W Yorkshire, England
[3] Univ Washington, Seattle, WA 98195 USA
[4] Guys & St Thomas NHS Fdn Trust, London, England
[5] RTI Hlth Solut, Res Triangle Pk, NC USA
[6] Novartis Pharma AG, Basel, Switzerland
[7] Novartis Pharmaceut, E Hanover, NJ USA
来源：
ANNALS OF THE RHEUMATIC DISEASES | 2016年 / 75卷
关键词：
D O I：
10.1136/annrheumdis-2016-eular.3949
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
FRI0463
引用
收藏
页码：605 / 605
页数：1
相关论文
共 50 条
  • [31] Secukinumab Improves Physical Function in Subjects With Plaque Psoriasis and Psoriatic Arthritis: Results from Two Randomized, Phase 3 Trials
    Gottlieb, Alice B.
    Langley, Richard G.
    Philipp, Sandra
    Sigurgeirsson, Bardur
    Blauvelt, Andrew
    Martin, Ruvie
    Papavassilis, Charis
    Mpofu, Shephard
    JOURNAL OF DRUGS IN DERMATOLOGY, 2015, 14 (08) : 821 - 833
  • [32] PREDICTION OF LOW DISEASE ACTIVITY IN PATIENTS WITH PSORIATIC ARTHRITIS TREATED WITH SECUKINUMAB IN REAL WORLD - DATA FROM THE GERMAN AQUILA STUDY
    Vodencarevic, A.
    Brandt-Juergens, J.
    Peterlik, D.
    Gmeiner, B.
    Kiltz, U.
    ANNALS OF THE RHEUMATIC DISEASES, 2023, 82 : 1126 - 1126
  • [33] Secukinumab improves physical function, quality of life, fatigue and work productivity in patients with active psoriatic arthritis: Results of a randomized, double-blind, placebo-controlled phase 3 trial (FUTURE 2)
    Gottlieb, A. B.
    Strand, V.
    McInnes, I. B.
    Marzo-Ortega, H.
    Kavanaugh, A.
    Kandala, S.
    Pricop, L.
    Mpofu, S.
    JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2015, 135 : S30 - S30
  • [34] Secukinumab improves active psoriatic arthritis and inhibits radiographic progression: Results of a phase 3 randomized, multicenter, double-blind, placebo-controlled study
    Mease, P.
    McInnes, I. B.
    Kirkham, B.
    Kavanaugh, A.
    Rahman, P.
    Van Der Heijde, D.
    Landewe, R.
    Nash, P.
    Pricop, L.
    Yuan, J.
    Richards, H.
    Mpofu, S.
    JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2015, 135 : S29 - S29
  • [35] SECUKINUMAB PROVIDES SUSTAINED REDUCTION IN FATIGUE IN PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS THROUGH 3 YEARS: LONG-TERM DATA FROM THE FUTURE 1 AND FUTURE 2 STUDIES
    Gossec, L.
    Kvien, T. K.
    Conaghan, P. G.
    Ostergaard, M.
    Gladman, D.
    Mease, P.
    Rasouliyan, L.
    Pricop, L.
    Gaillez, C.
    Jugl, S.
    ANNALS OF THE RHEUMATIC DISEASES, 2017, 76 : 949 - 949
  • [36] SECUKINUMAB PROVIDES SUSTAINED IMPROVEMENTS IN THE SIGNS AND SYMPTOMS OF ACTIVE PSORIATIC ARTHRITIS: 104 WEEKS RESULTS FROM A PHASE 3 TRIAL, FUTURE 2
    McInnes, I. B.
    Mease, P. J.
    Ritchlin, C.
    Rahman, P.
    Gottlieb, A.
    Kirkham, B.
    Kajekar, R.
    Delicha, E. M.
    Pricop, L.
    Mpofu, S.
    ANNALS OF THE RHEUMATIC DISEASES, 2017, 76 : 145 - 145
  • [37] Psoriatic patients treated with secukinumab reach high levels of minimal disease activity: results from the SUPREME study
    Campanati, Anna
    Diotallevi, Federico
    Radi, Giulia
    Molinelli, Elisa
    Brisigotti, Valerio
    Martina, Emanuela
    Paolinelli, Matteo
    Bianchelli, Tommaso
    Covi, Cristiano
    Bartezaghi, Marta
    Offidani, Annamaria
    EUROPEAN JOURNAL OF DERMATOLOGY, 2021, 31 (05) : 630 - 637
  • [38] SECUKINUMAB PROVIDES SUSTAINED REMISSION AND LOW DISEASE ACTIVITY RELATED TO DISEASE ACTIVITY INDEX FOR PSORIATIC ARTHRITIS (DAPSA): 2 YEAR RESULTS FROM THE FUTURE 2 STUDY
    Smolen, J. S.
    McInnes, I. B.
    Kvien, T. K.
    Pricop, L.
    Fox, T.
    Rasouliyan, L.
    Jugl, S.
    Gaillez, C.
    ANNALS OF THE RHEUMATIC DISEASES, 2017, 76 : 1323 - 1324
  • [39] Guselkumab Improves Anemia in Patients with Active Psoriatic Arthritis: Results From Two Phase 3 Randomized Controlled Clinical Trials
    Kavanaugh, Arthur
    Liu, Yang
    Rahman, Proton
    Mease, Philip
    Gossec, Laure
    Xu, Lillian
    Hsia, Elizabeth
    Shawi, May
    Han, Chenglong
    Neuhold, Marlies
    Deodhar, Atul
    JOURNAL OF RHEUMATOLOGY, 2022, 49 (07) : 788 - 789
  • [40] SECUKINUMAB PROVIDES SUSTAINED PASDAS RELATED LOW DISEASE ACTIVITY IN PSORIATIC ARTHRITIS: TWO YEAR RESULTS FROM THE FUTURE 2 STUDY
    Coates, Laura C.
    Gladman, Dafna
    Nash, Peter
    Fitzgerald, Oliver
    Kavanaugh, Arthur
    Rasouliyan, Lawrence
    Pricop, Luminita
    Ding, Kevin
    Gaillez, Corine
    RHEUMATOLOGY, 2018, 57
12345